Related Experiment Video
Updated: Dec 31, 2025

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
Inflammatory cardiomyopathies: short- and long-term outcomes after heart transplantation-a protocol for a systematic
Emanuele Bobbio1,2, Marie Lingbrant3,4, Bright I Nwaru5
1Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden. emanuele.bobbio@vgregion.se.
Insights
Heart transplantation outcomes for giant cell myocarditis and cardiac sarcoidosis are unclear. This systematic review synthesizes evidence on survival and rejection in these patients post-transplant.
Area of Science:
- Cardiology
- Transplantation Immunology
- Systematic Reviews
Background:
- Outcomes of heart transplantation (HTx) for giant cell myocarditis (GCM) and cardiac sarcoidosis (CS) remain controversial.
- Limited single-center data hinders comprehensive understanding of post-HTx results in these specific patient groups.
Purpose of the Study:
- To systematically review and synthesize existing literature on HTx outcomes in patients with GCM or CS.
- To compare the outcomes of HTx for GCM/CS against other transplant etiologies, focusing on survival, rejection, and recurrence.
Main Methods:
- Comprehensive literature search across major databases (PubMed, Scopus, Web of Science, EMBASE, Google Scholar) up to December 2019.
- Inclusion of observational and interventional population-based studies, with quality assessment using Newcastle-Ottawa and Cochrane tools.
- Narrative synthesis and meta-analysis of homogenous study estimates, adhering to MOOSE guidelines.
Main Results:
- This review aims to be the first synthesis of survival, acute cellular rejection, and disease recurrence data for GCM and CS patients undergoing HTx.
- The synthesis will provide critical insights into the suitability of HTx for these challenging conditions.
Conclusions:
- This systematic review and meta-analysis will clarify the efficacy and safety of heart transplantation for patients with giant cell myocarditis and cardiac sarcoidosis.
- Findings will inform clinical decision-making and guide future research priorities in cardiac transplantation for rare cardiomyopathies.
Abstract:
Heart transplantation (HTx) for patients with "giant cell myocarditis" (GCM) or "cardiac sarcoidosis" (CS) is still controversial. However, no single center has accumulated enough experience to investigate post-HTx outcome. The primary aim of this systematic review is to identify, appraise, and synthesize existing literature investigating whether patients who have undergone HTx because of GCM or CS have worse outcomes as compared with patients transplanted because of other etiologies. A systematic and comprehensive search will be performed using PubMed, Scopus, Web of Science, EMBASE, and Google Scholar, for studies published up to December 2019. Observational and interventional population-based studies will be eligible for inclusion. The quality of observational studies will be assessed using the Newcastle-Ottawa scale, while the interventional studies will be assessed using the Cochrane Effective Practice Organization of Care tool. The collected evidence will be narratively synthesized; in addition, we will perform a meta-analysis to pool estimates from studies considered to be homogenous. Reporting of the systematic review and meta-analysis will be in accordance with the Meta-analysis of Observational Studies in Epidemiology Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines. To our knowledge, this will be the first synthesis of outcomes, including survival, acute cellular rejection, and disease recurrence, in patients with either GCM or CS treated with HTx. Reviewing the suitability of HTx in this population and highlighting areas for further research will benefit both patients and healthcare providers. Trial registration: CRD42019140574.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Myocarditis I: Introduction
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

